Identification of SHC2 as a prognostic biomarker: from pan-cancer analysis to colon adenocarcinoma validation

Colon adenocarcinoma (COAD) is a malignant neoplasm of the digestive system characterized by a high incidence and significant mortality on a global scale. The majority of patients are diagnosed at intermediate to advanced stages of the disease. SHC-transforming protein 2 (SHC2), a member of the SHC family, has little known about its function in a variety of cancers, including COAD. This investigation thoroughly examined the expression characteristics, prognostic value, genomic variation and methylation patterns of SHC2 in pancarcinoma and discussed its correlation with tumor immune cell infiltration. Furthermore, we verified that SHC2 expression was elevated in COAD cell lines and that lowering SHC2 expression levels significantly reduced the invasion, migration and proliferation ability of COAD cell lines. Our results revealed that SHC2 is significantly dysregulated in COAD and that its expression level is closely related to patient prognosis, immune microenvironment remodeling, and drug sensitivity and affects tumor progression by regulating key signaling pathways. This study systematically reveals the value of SHC2 as a therapeutic target and prognostic indicator for COAD, offering a theoretical foundation for a thorough investigation of its molecular mechanism.